Practice-Changing Viral Hepatitis Data From AASLD 2022
Listen to expert insights from Nancy Reau, MD, on practice-changing viral hepatitis data from AASLD 2022, including HBV therapeutics in the pipeline, HCV management strategies, HDV screening and care linkage, fatty liver disease in patients with viral hepatitis, and the role of statins in patients with liver disease.
Decera Clinical Education Infectious Disease Podcast · Nancy Reau MD
Audio is streamed directly from the publisher (afp-928689-injected.calisto.simplecastaudio.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In this episode, Nancy Reau, MD, shares her thoughts on the most practice-changing viral hepatitis data from AASLD 2022, including:
- Novel therapeutics for HBV
- HCV management strategies
- HDV screening and linkage to care
- Fatty liver disease in persons with viral hepatitis
- Use of statins to decrease morbidity and mortality in persons with liver disease
Presenter:
Nancy Reau, MD
Professor of Medicine
Chief, Section of Hepatology
Associate Director
Solid Organ Transplantation
Richard B. Capps Chair of Hepatology
Rush University Medical Center
Chicago, Illinois
Link to full program:
https://bit.ly/3Y1tD6f
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.